• The US Department of Justice has reportedly prepared a civil antitrust lawsuit against major egg producers, including Cal-Maine Foods, over alleged price-fixing in 2024 and 2025, heightening regulatory scrutiny of the industry.
• This legal threat emerges just as Cal-Maine has been emphasizing a portfolio shift toward higher-margin specialty eggs and Prepared Foods, raising questions about how future pricing practices might evolve under closer oversight.
• Next, we will examine how the potential antitrust lawsuit, and its impact on Cal-Maine’s pricing power, affects the existing investment narrative.

We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Cal-Maine Foods Investment Narrative Recap

To own Cal Maine Foods, you need to believe in eggs as a steady, low cost protein business where scale, efficiency and mix shift toward specialty and prepared products can support durable profitability. The reported Department of Justice antitrust lawsuit introduces a new layer of regulatory risk around pricing, which could matter more in the near term than traditional concerns like avian influenza if it constrains how Cal Maine uses its scale to price across the portfolio.

The recent fiscal Q3 2026 update is especially relevant here, with management highlighting that specialty eggs and Prepared Foods now account for more than half of net sales and that market conditions appear more stable. If pricing practices in these higher margin categories face tighter oversight, it could influence how effectively Cal Maine converts that mix shift into earnings resilience, particularly as the industry rebuilds capacity and competition intensifies.

Yet investors should also be aware that closer scrutiny of Cal Maine’s pricing could interact in unexpected ways with...

Cal-Maine Foods' narrative projects $2.7 billion revenue and $114.1 million earnings by 2028. This requires a 15.0% yearly revenue decline and an earnings decrease of about $1.2 billion from $1.3 billion today.

Uncover how Cal-Maine Foods' forecasts yield a $98.00 fair value, a 30% upside to its current price.

Exploring Other Perspectives

Fourteen members of the Simply Wall St Community currently place Cal Maine’s fair value anywhere between US$16.89 and US$148 per share, with estimates spread across almost every bucket in that range. When you set those opinions against the emerging antitrust risk around alleged price fixing, it underlines how important it is to weigh several different views on how Cal Maine’s pricing power might shape future performance.

Explore 14 other fair value estimates on Cal-Maine Foods - why the stock might be worth as much as 97% more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Cal-Maine Foods research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• Our free Cal-Maine Foods research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Cal-Maine Foods' overall financial health at a glance.

Seeking Other Investments?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.
• The latest GPUs need a type of rare earth metal called Dysprosium and there are only 31 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.